CollPlant Biotechnologies Ltd (OPHI) CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine enterprise operating across the United States, Canada, and Europe. The company primarily engages in the three-dimensional (3D) bioprinting of tissues and organs, alongside developing solutions for medical aesthetics. All of CollPlant's offerings are underpinned by its proprietary plant-based genetic engineering technology, which facilitates the production of recombinant type I human collagen. Its diverse product portfolio encompasses BioInks engineered for 3D tissue and organ fabrication; dermal and soft tissue fillers designed to diminish wrinkles; and innovative breast implants, both 3D bioprinted and injectable, aimed at promoting breast tissue regeneration. CollPlant also provides a 3D bioprinted regenerative soft tissue matrix. Specialized products include VergenixSTR, a soft tissue repair matrix targeting tendinopathy, and VergenixFG, an advanced wound care treatment for deep surgical incisions and persistent wounds such as diabetic, venous, and pressure ulcers, burns, and bedsores. The company maintains strategic collaboration agreements with numerous partners, including 3D Systems Corporation, CellInk (a BICO Group company), the Advanced Regenerative Manufacturing Institute, the RegenMed Development Organization, Israel's Technion Institute of Technology, AbbVie, and STEMCELL. Established in Rehovot, Israel, in 2004, the company was formerly known as CollPlant Holdings Ltd. before adopting its current name in June 2019.
Sector: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Industry: Medical - Specialties
CollPlant Biotechnologies Ltd. NASDAQ:OPHI Healthcare · Biotechnology
Mkt Cap $14.27M
EV -
SI 2.9%
Net Cash/Sh -
CLOSED Prev close $3.96 +17.17%Close $4.64 VOL 27K $ Vol $97K RVOL 0.36x
Mkt Cap $14.27M
EV -
VOL 27K sh
$ Vol $97K
RVOL 0.36×
SI 2.9%
Net Cash/Sh -
Press Release
CollPlant to Begin Trading on Nasdaq Under New Ticker Symbol “OPHI”
CollPlant Biotechnologies' ordinary shares will begin trading on Nasdaq under the new ticker symbol OPHI at the open on November 13, 2026, replacing CLGN, which remains active through the November 12 close. No shareholder action is required, and the CUSIP number and Nasdaq listing are unchanged. The rebrand reflects a strategic expansion into photonic computing via subsidiary LightSolver and its laser-based LPU technology.
• 5d ago AI analysis › Press Release
LightSolver to Unveil the First Public Demonstration of its All-Optical Computer at SC26
CollPlant's subsidiary LightSolver will give the first public demonstration of its all-optical Laser Processing Unit at the SC26 supercomputing conference in Chicago, November 15-20, 2026. The LPU computes using interacting laser beams rather than electronics and is designed to work alongside GPUs; LightSolver will also present benchmark results from a paid multi-year Boeing program on PDE-based corrosion simulation. Subject to shareholder and Nasdaq approval, CollPlant intends to rebrand as OptiPhi Computing Ltd.
• 6d ago AI analysis › Press Release
LightSolver Secures ~$1.8 Million Grant from Israel’s Innovation Authority to Advance its Laser Processing Unit (LPU)
CollPlant's subsidiary LightSolver received an approximately $1.8 million grant from the Israel Innovation Authority to advance its Laser Processing Unit (LPU), an all-optical laser-based computing platform. The program funds next-generation LPU hardware for solving PDEs, expanded LPU Lab capabilities, and integration into heterogeneous HPC environments alongside CPUs and GPUs. The grant adds to institutional support including a Boeing partnership, paid work with Israel's Ministry of Defense, and European Innovation Council funding. CollPlant also intends, subject to shareholder approval, to rename itself OptiPhi Computing Ltd.
• 12d ago AI analysis › Press Release
CollPlant Announces Proposed Name Change to OptiPhi Computing Reflecting Expansion to Computing with Light
CollPlant Biotechnologies (Nasdaq: CLGN) announced a board-approved proposal to rename itself OptiPhi Computing Ltd. and change its ticker from CLGN to OPHI, reflecting its expansion into photonic computing following the September 2026 LightSolver acquisition. The change requires shareholder approval at a general meeting scheduled for November 24, 2026, plus Nasdaq confirmation; until effective, the company continues trading as CLGN.
• 13d ago AI analysis › Press Release
LightSolver Secures Paid Collaboration with the Israel Ministry of Defense for the Development of Photonic Computing Technology
CollPlant's subsidiary LightSolver signed a paid multi-year framework agreement with the Israel Ministry of Defense's DDR&D for development and delivery of its Laser Processing Unit (LPU). The deal follows earlier proof-of-concept work and includes an initial order covering the first 12 months, adding a major government defense customer alongside LightSolver's existing Boeing program.
• 19d ago AI analysis › Press Release
COLLPLANT ANNOUNCES A $3.7 MILLION PRIVATE PLACEMENT
CollPlant agreed to sell 989,301 ordinary shares plus warrants on 1,483,952 shares in a private placement at $3.74 per share-and-warrant unit, for approximately $3.7 million in gross proceeds. The raise, led primarily by existing investors, is expected to close around October 14, 2026, with H.C. Wainwright and Rodman & Renshaw acting as placement agents.
• 1mo ago AI analysis › Press Release ● Major
LightSolver Files U.S. Provisional Patent Application Expanding its Photonic Computing Platform to Advanced Scientific and Engineering Simulations
prnewswire.com • 1mo ago Press Release
COLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant reported Q2 2026 GAAP revenue of $108,000, down from $179,000 a year earlier, with a GAAP gross loss of $456,000 and a net loss of $2.7 million ($1.89 basic loss per share). The company completed its acquisition of photonic-computing startup LightSolver in September 2026, marking a strategic pivot into high-performance computing alongside its legacy rhCollagen regenerative-medicine platform; LightSolver co-founder Dr. Ruti Ben Shlomi joined the board.
• 1mo ago AI analysis › Press Release
LightSolver, a CollPlant Company, and HLRS Joint Research Demonstrated Photonic Computing Can significantly Accelerate Fundamental HPC Workloads
CollPlant announced peer-reviewed joint research by subsidiary LightSolver and Germany's HLRS supercomputing center showing its Laser Processing Unit (LPU) photonic architecture can accelerate sparse linear solvers. Benchmarked via an emulator against GPU-based state-of-the-art algorithms, the study projected time-to-solution acceleration of roughly 40x to more than 80,000x, depending on the problem. The paper was published in the proceedings of the 23rd ACM International Conference on Computing Frontiers.
• 1mo ago AI analysis › Press Release
CollPlant Regains Compliance with Nasdaq Minimum Bid Price Requirement
CollPlant Biotechnologies has regained compliance with Nasdaq's minimum bid price requirement after its closing bid held at or above $1.00 for ten consecutive business days from September 4 to September 18, 2026. The matter dates to a deficiency notice issued March 23, 2026, after the shares traded below $1.00 for 30 consecutive business days; Nasdaq has formally confirmed the compliance matter is now closed.
• 1mo ago AI analysis › Press Release
CollPlant to Host LightSolver Investor Webinar on September 17, 2026
CollPlant Biotechnologies' subsidiary LightSolver will host an investor webinar on Thursday, September 17, 2026, at 8:30 a.m. Eastern Time. LightSolver, developer of the Laser Processing Unit (LPU) photonic computing architecture, became a CollPlant subsidiary following the acquisition announced September 3, 2026, diversifying the regenerative-medicine company into advanced high-performance computing for aerospace, defense, and Physical AI workloads.
• 2mo ago AI analysis › Press Release ● Major
COLLPLANT APPOINTS DR. RUTI BEN SHLOMI TO ITS BOARD OF DIRECTORS FOLLOWING CLOSING OF LIGHTSOLVER ACQUISITION
CollPlant Biotechnologies appointed Dr. Ruti Ben Shlomi, founder and CEO of LightSolver, to its board of directors, effective immediately following completion of the LightSolver acquisition first announced on September 3, 2026. LightSolver builds photonic high-performance computing around its Laser Processing Unit (LPU), an energy-efficient all-optical platform that uses coupled lasers to accelerate scientific simulation, engineering, optimization and Physical AI workloads. No financial terms of the acquisition were disclosed in this release.
• 2mo ago AI analysis › Press Release ● Major
COLLPLANT COMPLETES ACQUISITION OF LIGHTSOLVER, ENTERING THE PHOTONIC COMPUTING SECTOR
CollPlant has completed its acquisition of LightSolver, an Israeli deep-tech company developing the Laser Processing Unit, a pure photonic computing platform aimed at high-performance computing workloads. Consideration was equity-centric: upfront ordinary shares, pre-funded warrants, and a $5 million investment in LightSolver at closing, with additional milestone-based warrants tied to future technological and commercial objectives.
• 2mo ago AI analysis › Press Release ● Major
COLLPLANT ANNOUNCES REVERSE SHARE SPLIT
CollPlant announced a one-for-ten reverse share split effective September 4, 2026, following shareholder approval at an Extraordinary General Meeting. The strategic move aims to regain compliance with the Nasdaq Capital Market minimum bid price requirement for continued listing.
• 2mo ago AI analysis › Press Release
COLLPLANT IS ACQUIRING LIGHTSOLVER- ENTERS SUPERCOMPUTING AND PHOTONIC COMPUTING MARKETS
prnewswire.com • 2mo ago Press Release
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT
CollPlant priced a $2.6 million private placement, issuing 7.65 million ordinary shares at a combined purchase price of $0.34 per share and accompanying warrants. The deal includes unregistered Series A and Series B warrants to purchase nearly 23 million additional shares, both exercisable at $0.34 pending shareholder approval. Net proceeds are designated for general corporate purposes, R&D funding, and evaluating strategic combinations; H.C. Wainwright & Co.
• 4mo ago AI analysis › Press Release
COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant Biotechnologies reported Q1 2026 GAAP revenue of $73,000, a 96% decline year-over-year, driven by the absence of a $2.0 million one-time milestone payment received in the prior year. The company posted a GAAP net loss of $3.1 million ($0.23 per share), widening from a $1.5 million loss in Q1 2025, despite reducing operating expenses by approximately 18% through a 50% headcount reduction.
• 5mo ago AI analysis › Press Release
CollPlant Issues Letter to Shareholders
prnewswire.com • 7mo ago